摘要：<正>美宝湿润烧伤膏是由我国烧伤学科带头人徐荣祥教授研究发明并监制的,专门用于治疗各种烧、烫、灼伤的药物,具有清热解毒,止痛,生肌之效。近年研究显示,缺氧诱导因子及血管内皮生长因子在创面愈合中均起着十分

摘要：目的:观察湿润烧伤膏联合重组人碱性成纤维细胞生长因子(rh-bFGF)凝胶治疗浅Ⅱ度烧伤患者的疗效及对创面肉芽组织缺氧诱导因子-1α(HIF-1α)、血管内皮生长因子(VEGF)蛋白表达的影响。方法:选取天津市第一中心医院2018年12月到2020年12月之间收治的浅Ⅱ度烧伤患者70例,根据住院号单双数分为对照组和实验组两组,各35例。对照组给予rh-bFGF凝胶治疗,实验组给予湿润烧伤膏联合rh-bFGF凝胶治疗,两组均治疗2周。对比两组疗效、创面愈合率、症状消失时间、不良反应发生率、血清炎症因子水平变化和创面肉芽组织HIF-1α、VEGF蛋白表达变化。结果:实验组的临床总有效率、创面愈合率均高于对照组(P<0.05)。实验组的肿胀、疼痛、红斑、水疱、渗液症状消失时间均短于对照组(P<0.05)。治疗2周后,两组患者血清白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、超敏C反应蛋白(hs-CRP)水平较治疗前下降(P<0.05),且实验组低于对照组(P<0.05)。治疗2周后,实验组患者创面肉芽组织VEGF蛋白表达水平高于对照组,HIF-1α蛋白表达水平低于对照组(P<0.05)。对照组的不良反应发生率为11.43%,与实验组的5.71%对比差异无统计学意义(P>0.05)。结论:与单用rh-bFGF凝胶治疗相比,联合湿润烧伤膏治疗浅Ⅱ度烧伤患者可更好地促进创面愈合,改善患者症状,同时还可改善血清炎症因子水平及创面肉芽组织HIF-1α、VEGF蛋白表达,安全可靠。

摘要：目的:本项目拟通过PI3K/AKT/HIF-1α信号通路探讨再生医疗技术促进慢性难愈合创面修复的部分分子机制,结合前期课题研究结果,进一步完善慢性难愈合创面的病理机制研究,为慢性难愈合创面的治疗提供思路及参考。同时也为完善再生医疗技术在慢性难愈合创面上的作用机制,为再生医疗技术在临床上的推广应用增强科学理论依据。方法:90只从广西医科大学购买的SPF级别大鼠,均为雄性大鼠。购买后饲养在右江民族医学院SPF级别动物科学实验中心,随机分为:空白组、急性组及慢性难愈合创面组,其中空白组的大鼠不做任何有损伤性处理,急性组行全层皮肤缺损处理,慢性难愈合创面组是首先进行全层皮肤缺损处理,再参照付小兵等全层皮肤缺损法和沈氏改良塑料环肉芽肿定量法经改进制成的大鼠慢性难愈合创面。即在行全层皮肤切除后注射氢化可的松。慢性难愈合创面组再按造模后的处理方法不同随机分为慢创组(即模型组),贝复新组及美宝组,慢创组即造模后无药物干预治疗;贝复新组是造模后使用贝复新药物干预治疗;美宝组是造模后使用再生医疗技术(moist exposed burn therapy/moist exposed burn ointment,MEBT/MEBO)干预治疗。各组创面制备后立即用药治疗。各组换药前均以1/5000呋喃西林液清洁创面,每日换药2次。动物模型制备完成后,每天使用SONY摄像机拍摄创面,以便创面愈合率分析;各组于造模后3d、7d、14d共3个时相点随机取6只大鼠腹腔麻醉后,切取整个创面肉芽组织。所取组织部分放入甲醛中固定,之后行HE染色及CD31免疫组化检查,余下样品迅速冻于-80℃冰箱,收集所有时相点的组织标本后统一进行Western blot检测。从宏观的创面愈合率及病理切片的炎症细胞浸润和血管新生,到微观的蛋白分子信号转导通路上研究慢性难愈合创面的病理机制及再生医疗技术在慢性难愈合创面的潜在机制。结果:(1)创面愈合率,除空白组外,各组愈合率均逐渐上升,在14d观察时相点,急性组创面的愈合率为:0.965±0.019,慢创组创面的愈合率为:0.468±0.013,贝复新组创面的愈合率为:0.975±0.007,美宝组创面的愈合率为:0.974±0.002。慢创组与急性组的P<0.001,慢创组与贝复新组的P<0.001,慢创组与美宝组的P<0.001,均有统计学差异。急性组与贝复新组的P=0.630,急性组与美宝组的P=0.709,贝复新...

摘要：The present study aimed to investigate the expression and predictive value of serum hypoxia-inducible factor-1α (HIF-1α) and vascular endothelial growth factor (VEGF) in patients with burns following treatment. A total of 84 patients with burns treated in Jinan City People's Hospital (Jinan, China) between June 2015 and August 2017 were selected and their clinical information was collected. The expression levels of HIF-1α and VEGF before and after treatment were detected via ELISA, and HIF-1α and VEGF levels in patients with effective and ineffective treatment were compared. The predictive values of HIF-1α and VEGF in clinical efficacy were determined using receiver operating characteristic (ROC) curves, and independent risk factors affecting treatment inefficacy were analyzed via multivariate logistic regression. It was revealed that HIF-1α decreased significantly (P<0.05) while VEGF significantly increased in patients after treatment. Patients with effective treatment presented significantly lower HIF-1α levels and higher VEGF levels compared with those with ineffective treatment. The ROC curve indicated that the area under the curve (AUC) of HIF-1α for treatment efficacy was 0.795, the 95% CI was 0.666-0.924, the specificity and sensitivity were 68.75 and 80.88%, respectively, and the Youden index was 49.63%. For VEGF, the AUC, 95% CI, specificity, sensitivity and Youden index were 0.826, 0.725-0.928, 68.75, 82.35 and 51.10% respectively. Moreover, under the joint detection of HIF-1α and VEGF, the AUC was 0.847, 95% CI was 0.746-0.947, specificity and sensitivity were 87.50 and 66.18%, respectively, with a Youden index of 53.68%. Multivariate analysis demonstrated that higher HIF-1α level, lower VEGF level and higher burn degree before treatment were independent risk factors for treatment inefficacy. HIF-1α levels decreased and VEGF levels increased in burn patients after treatment. HIF-1α and VEGF before treatment may therefore serve as predictors for treatment efficacy.